Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters - AstraZeneca (NASDAQ:AZN), Eli Lilly and Co (NYSE:LLY), AbbVie (NYSE:ABBV), Regeneron Pharmaceuticals (NASDAQ:REGN)

In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported citing the Washington University School of Medicine.
The latest study included three of the four variants that have been designated "variants of concern" by the WHO.
The FDA in April revoked the emergency use authorization of Eli Lilly And Co's LLY single antibody therapy, bamlanivimab, amid resistance due to the variants.
The researchers evaluated the FDA authorized combination therapies made by Regeneron Pharmaceuticals Inc REGN, Eli Lilly, and single antibody therapy, sotrovimab by Vir Biotechnology Inc VIR and GlaxoSmithKline Plc GSK.
They also assessed the antibodies in clinical trials by AbbVie Inc ABBV, Vir, and AstraZeneca Plc AZN.